Improved glycemic control enhances the incretin effect in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4702-4708

  An, Zhibo ^a   Prigeon, Ronald L ^b   D'Alessio, David A ^a,c  

^a Division of Endocrinology   (United States)

^b Education and Clinical Center   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LONG ACTING INSULIN;

ADULT; ARTICLE; C PEPTIDE BLOOD LEVEL; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; FEMALE; GLUCOSE INTAKE; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN TREATMENT; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN RESISTANCE; INSULIN, LONG-ACTING; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; OVERWEIGHT;

EID: 84889877214     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1199     Document Type: Article

References (39)

1. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876-913
2. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52
3. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492-498
4. Drucker DJ. The biology of incretin hormones. Cell Meta. 2006; 3(3):153-165
5. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993;76(4):912-917
6. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res. 2004;36(11-12):867-876
7. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide- 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705
8. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57(5):1340-1348
9. Salehi M, Aulinger B, Prigeon RL, D'Alessio DA. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. 2010; 59(6):1330-1337
10. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-613
11. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723
12. Meier JJ, NauckMA.Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab. 2008; 4(11):606-607
13. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91(1):301-307
14. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45(8):1111-1119
15. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagonlike peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-744
16. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care. 2003;26(3):791-798
17. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52(2):380-386
18. Ferrannini E. The stunned β cell: A brief history. Cell Metab. 2010; 11(5):349-352
19. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80(4):1037-1044
20. Ferner RE, Rawlins MD, Alberti KG. Impaired β-cell responses improve when fasting blood glucose concentration is reduced in noninsulin- dependent diabetes. Q J Med. 1988;66(250):137-146
21. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type 2 diabetes mellitus. Diabetes. 1985;34(3):222-234
22. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E. Improved β-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol (Copenh). 1988; 118(3):365-373
23. Turner RC, McCarthy ST, Holman RR, Harris E. β-Cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J. 1976;1(6020):1252-1254
24. Vague P, Moulin JP. The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism. 1982;31(2):139-142
25. Hidaka H, Nagulesparan M, Klimes I, et al. Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type 2 diabetics. J Clin Endocrinol Metab. 1982; 54(2):217-222
26. Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon- like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52(2): 199-207
27. Hojberg PV, Zander M, Vilsboll T, et al. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucoseinduced insulin secretion in patients with type 2 diabetes. Diabetologia. 2008;51(4):632-640
28. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes. 2011;60(9):2308-2314
29. VanCauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992;41:368-377
30. Wallace TM, Levy JC, Matthew DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495
31. PorteDJr. Banting lecture 1990. β-Cells in type 2 diabetes mellitus. Diabetes. 1991;40(2):166-180
32. Kahn SE. Clinical review 135: The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86(9):4047-4058
33. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest. 1984;74(4):1318-1328
34. Henchoz E, D'Alessio DA, Gillet M, et al. Impaired insulin response after oral but not intravenous glucose in heart- and liver-transplant recipients. Transplantation. 2003;76(6):923-929
35. Andersen DK, Elahi D, Brown JC, Tobin JD, Andres R. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest. 1978;62(1):152-161
36. Tong J, Aulinger B, Salehi M, D'Alessio D. Comparison of one and two-day methods for measuring the incretin effect. Diabetes. 2009; 58(suppl 1):A376-A376
37. Giugliano D, Di Pinto P, Ceriello A, et al. Glycemic control with an artificial pancreas improves insulin responses to both oral and glucose in nonobese noninsulin-dependent diabetic subjects. Acta Diabetol Lat. 1985;22(3):203-213
38. Hojberg PV, Vilsboll T, Zander M, et al. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with type 2 diabetes. Diabet Med. 2008;25(11): 1268-1275
39. Salehi M, Aulinger B, D'Alessio DA. Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes. 2012;61(11):2728-2733